What it's for (Indications)
- Lisuride, an ergoline derivative and potent dopamine agonist, is primarily indicated for the management of Parkinson's disease, either as monotherapy in early stages or as an adjunct to levodopa therapy in more advanced cases to reduce "off" periods and improve motor fluctuations.
- It is also effectively used in the treatment of hyperprolactinemia, encompassing conditions such as prolactin-secreting pituitary adenomas (prolactinomas), galactorrhea-amenorrhea syndrome, and other manifestations of excessive prolactin secretion.
- The therapeutic goal in these hyperprolactinemic states is to reduce prolactin levels, thereby restoring normal gonadal function and reducing tumor size.
- Historically, it has also been explored for migraine prophylaxis, although this is a less common current indication due to the availability of newer agents and its side effect profile.
- Its utility extends to situations requiring sustained dopaminergic stimulation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of lisuride must be carefully individualized and titrated according to the patient's specific indication, clinical response, and tolerability, always starting with a low dose and increasing gradually. For Parkinson's disease, therapy typically initiates with 0.1 mg to 0.2 mg daily, divided into two or three doses, with slow increments of 0.1 mg every few days to weeks based on response and tolerability. The usual therapeutic range can vary significantly, often between 0.6 mg to 5 mg per day, though some patients may require higher doses, up to 10 mg or more daily, under specialist supervision. For hyperprolactinemic states, an initial dose of 0.1 mg daily at bedtime may be prescribed, gradually increasing to a maintenance dose typically ranging from 0.2 mg to 0.6 mg daily, depending on prolactin levels and clinical response. It is crucial to administer lisuride with food to mitigate gastrointestinal side effects. Abrupt discontinuation should be avoided due to the risk of dopamine agonist withdrawal syndrome (DAWS), requiring a slow, gradual taper. |
Safety & Warnings
Common Side Effects
- Common side effects associated with lisuride are frequently dose-dependent and include gastrointestinal disturbances such as nausea, vomiting, abdominal discomfort, constipation, and dyspepsia, particularly during initiation and dose titration.
- Cardiovascular effects may manifest as orthostatic hypotension, dizziness, and syncope, especially upon standing.
- Central nervous system adverse events can involve somnolence, insomnia, headaches, confusion, hallucinations, delusions, and dyskinesias, especially when used in conjunction with levodopa.
- Other notable side effects include peripheral edema (swelling of ankles/feet), asthenia, and, importantly, the potential for impulse control disorders (ICDs) such as pathological gambling, increased libido, hypersexuality, compulsive shopping, and binge eating.
- Less common but serious adverse effects include erythromelalgia, skin rashes, and, most critically, fibrotic reactions, which are discussed further in the "Black Box Warning" section.
- Visual disturbances and blurred vision can also occur.
Serious Warnings
- Black Box Warning: Serious Warnings: Fibrotic Reactions and Impulse Control Disorders Lisuride, an ergoline derivative, is associated with a significant risk of serious fibrotic and valvular complications. Prolonged use of ergoline dopamine agonists, including lisuride, has been linked to the development of serious fibrotic reactions, notably pleural fibrosis, retroperitoneal fibrosis, and cardiac valvulopathy (e.g., thickening, restriction, or insufficiency of heart valves, particularly the mitral, aortic, and tricuspid valves). These fibrotic conditions can lead to severe organ dysfunction, including respiratory compromise, kidney failure, and heart failure, and may necessitate surgical intervention. Patients should undergo a thorough cardiovascular evaluation, including baseline echocardiography, before initiating lisuride therapy and periodically thereafter, especially with long-term use. Regular monitoring for signs and symptoms of fibrotic reactions, such as dyspnea, persistent cough, pleuritic chest pain, renal insufficiency, abdominal pain, or the development of new cardiac murmurs, is imperative. If fibrotic changes are suspected or confirmed, discontinuation of lisuride should be considered, as resolution may not always occur and damage can be irreversible. Furthermore, lisuride can induce impulse control disorders (ICDs), including pathological gambling, increased libido, hypersexuality, compulsive spending or shopping, and binge eating. These behaviors can emerge suddenly, even in patients without a prior history, and can have profound personal, social, and financial consequences. Patients and caregivers must be informed of this risk and instructed to report any new or increased compulsive behaviors immediately. Dose reduction or discontinuation of lisuride should be considered if ICDs develop, as they often resolve or improve upon drug cessation or dose reduction. Prompt recognition and management are crucial to mitigate these severe adverse effects.
- Lisuride, as a potent dopamine agonist and ergoline derivative, requires careful consideration and monitoring for several significant safety concerns.
- Patients should be closely monitored for the development of impulse control disorders (ICDs), including pathological gambling, hypersexuality, compulsive spending, and binge eating, as these can manifest suddenly and have severe psycho-social and financial consequences.
- Psychiatric evaluation is recommended for patients with a history of psychosis or severe psychiatric disorders, as lisuride can exacerbate these conditions.
- Orthostatic hypotension, particularly at the initiation of therapy or during dose escalation, necessitates cautious dosing, patient education on postural changes, and regular monitoring of blood pressure.
- Patients should be advised about the potential for sudden onset of sleep or extreme somnolence, which can impair the ability to drive or operate machinery, even in the absence of prior warning signs.
- Regular cardiovascular assessment is crucial, especially in patients with pre-existing cardiac conditions or those at risk of fibrotic valvulopathy.
- Abrupt withdrawal of lisuride can lead to a severe dopamine agonist withdrawal syndrome (DAWS), characterized by symptoms resembling neuroleptic malignant syndrome, including fever, rigidity, mental status changes, and autonomic instability; therefore, discontinuation must always be gradual under medical supervision.
- The potential for serious fibrotic reactions, particularly affecting the pleura, retroperitoneum, and cardiac valves, is a critical concern requiring vigilant monitoring, as detailed in the "Black Box Warning" section.
How it Works (Mechanism of Action)
Lisuride is a semi-synthetic ergoline derivative that primarily acts as a potent dopamine receptor agonist. Its principal therapeutic effects are mediated through direct stimulation of D2 dopamine receptors in the brain. In Parkinson's disease, this D2 agonism in the nigrostriatal pathway helps to compensate for the degeneration of dopaminergic neurons, alleviating motor symptoms such as bradykinesia, rigidity, and tremor. In hyperprolactinemic states, lisuride's D2 agonism in the anterior pituitary gland directly inhibits the secretion of prolactin, thereby normalizing prolactin levels and reversing associated clinical manifestations like galactorrhea, amenorrhea, and reducing the size of prolactinomas. Beyond D2 agonism, lisuride also exhibits some D1 receptor antagonism and has complex interactions with various serotonin receptors (e.g., 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C) and alpha-adrenergic receptors. These additional receptor affinities may contribute to its overall pharmacological profile, including potential side effects and, in some contexts, its historical use in migraine prophylaxis due to its 5-HT receptor modulation. Its long-acting nature is attributed to its binding characteristics at these receptors, providing sustained therapeutic effects.
Commercial Brands (Alternatives)
No other brands found for this formula.